Enhancing immune responses to control HIV infection
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection
['FUNDING_R01'] · ALBERT EINSTEIN COLLEGE OF MEDICINE · NIH-11091550
This study is testing a new treatment that helps boost your immune system to better fight HIV, using special substances that encourage your body's immune cells to work harder, especially after you stop taking HIV medication.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ALBERT EINSTEIN COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (BRONX, UNITED STATES) |
| Trial ID | NIH-11091550 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative strategies to enhance the immune system's ability to control HIV infection. It utilizes a novel approach involving infusible biologics called synTacs, which link MHC molecules with virus-derived peptides to stimulate the expansion of CMV-specific CD8 T cells. By mobilizing these immune cells, the goal is to prevent the reactivation of HIV from latent reservoirs after stopping antiretroviral therapy. Patients may receive these treatments to improve their immune response against HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy and are interested in exploring new treatment options.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, reducing the need for lifelong antiretroviral therapy.
How similar studies have performed: Other research has shown promise in enhancing immune responses against HIV using similar immunotherapeutic approaches, indicating potential for success in this novel strategy.
Where this research is happening
BRONX, UNITED STATES
- ALBERT EINSTEIN COLLEGE OF MEDICINE — BRONX, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GOLDSTEIN, HARRIS — ALBERT EINSTEIN COLLEGE OF MEDICINE
- Study coordinator: GOLDSTEIN, HARRIS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus